Core Insights - Novo Nordisk reported a 15% sales growth in the third quarter, surpassing forecasts, which is a positive development for the company amid a significant restructuring effort [1] Company Performance - The sales growth of 15% indicates strong demand for Novo Nordisk's products, particularly Wegovy, which is contributing to the company's overall performance [1] - The new CEO is experiencing a boost in confidence due to the better-than-expected sales figures, which may support the ongoing restructuring initiatives [1]

Core Insights - The financial report for the first nine months of 2025 shows robust sales growth, but the company has narrowed its guidance due to lower growth expectations for GLP-1 treatments [2][4] Financial Performance - Net sales reached DKK 229.9 billion, a 12% increase compared to DKK 204.7 billion in the same period of 2024, with a 15% growth at constant exchange rates (CER) [2][4] - Operating profit increased by 5% to DKK 95.9 billion, with a 10% growth at CER, impacted by one-off restructuring costs of approximately DKK 9 billion [2][4] - Net profit rose by 4% to DKK 75.5 billion, with diluted earnings per share increasing by 4% to DKK 16.99 [2][4] Sales Breakdown - Sales in US Operations increased by 12% in Danish kroner and 15% at CER, while International Operations saw a 13% increase in Danish kroner and 16% at CER [4] - Sales within Diabetes and Obesity care grew by 12% to DKK 215.7 billion, driven by a 37% increase in Obesity care sales to DKK 59.9 billion and a 7% increase in GLP-1 diabetes sales [4] Research and Development - The US FDA approved Wegovy® for the treatment of MASH, and the company announced the acquisition of Akero Therapeutics, adding a potential first-and-best-in-class asset [4] - The phase 3 development of cagrilintide for weight management has been initiated, with the potential to be the first amylin monotherapy treatment on the market [4] Future Outlook - For the full-year 2025, sales growth is now expected to be between 8-11% at CER, with operating profit growth projected at 4-7% at CER, reflecting a negative impact of around DKK 8 billion from the company-wide transformation [4] - The guidance narrowing is attributed to lowered growth expectations for GLP-1 treatments within diabetes and obesity [4]

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more and more heated. ...

Core Insights - Novo Nordisk and Eli Lilly are set to gain Medicare and Medicaid coverage for their leading weight-loss drugs [1] Company Summary - Novo Nordisk will benefit from the expanded coverage of its weight-loss drugs under Medicare and Medicaid [1] - Eli Lilly is also positioned to gain from the same coverage expansion for its weight-loss medications [1] Industry Summary - The inclusion of weight-loss drugs in Medicare and Medicaid signifies a potential shift in the healthcare landscape, impacting the pharmaceutical industry [1] - This development may lead to increased market access and sales growth for companies like Novo Nordisk and Eli Lilly in the weight-loss drug segment [1]

Skip to Main Content Skip to Search This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera By Josh Nathan-Kazis Updated Nov 04, 2025, 1:35 pm EST / Original Nov 04, 2025, 12:26 pm EST Share Resize Reprints VKTX Buying ...

Core Viewpoint - Metsera stock (NASDAQ: MTSR) experienced a significant increase of approximately 20% following the announcement that Novo Nordisk's revised $10 billion acquisition proposal is considered "superior" to that of Pfizer [1] Company Summary - Metsera, a biotech company focused on obesity, has seen its stock price surge due to the competitive acquisition interest from major pharmaceutical companies [1] - The acquisition proposal from Novo Nordisk, valued at $10 billion, highlights the growing importance of obesity treatment in the biotech sector [1] Industry Summary - The biotech industry is witnessing heightened activity in mergers and acquisitions, particularly in the obesity treatment segment, as major players like Novo Nordisk and Pfizer vie for strategic positions [1] - The competitive landscape in the obesity-focused biotech market is intensifying, with significant financial commitments being made by leading pharmaceutical companies [1]

Financial Data and Key Metrics Changes - The company achieved record performance in the third quarter, with revenues from continuing operations of $1.8 billion, a 12% increase year-over-year [7] - Adjusted EBITDA from continuing operations increased by 22% to $667 million, while consolidated adjusted EBITDA, including discontinued operations, rose by 15% to $743 million [8] - Earnings per diluted share from continuing operations were $5.97, a 23% increase, and total earnings per diluted share, including discontinued operations, were $6.85, a 16% increase [8] Business Line Data and Key Metrics Changes - Aggregates revenues reached $1.5 billion, a 17% increase, with gross profit up 21% to $531 million and gross margin expanding to 36% [6][16] - The specialties business reported record quarterly revenues of $131 million, a 60% increase, and gross profit increased by 20% to $34 million [6][17] - Revenues from the continuing operations building materials business, which includes aggregates, asphalt, and paving, increased by 10% to $1.7 billion, with gross profit rising 16% to $585 million [16] Market Data and Key Metrics Changes - The value of state and local government highway, bridge, and tunnel contract awards increased by 10% year-over-year, reaching $128 billion for the 12-month period ending September 30, 2025 [10] - Heavy non-residential construction demand remains steady, driven by data center development and recovery in warehousing and distribution [12][13] - The National Association of Home Builders' Housing Market Index rose to its highest level since April, indicating improved builder confidence [14] Company Strategy and Development Direction - The company is focused on disciplined growth and operational excellence, with a strategic plan that includes maintaining world-class safety standards and delivering attractive price-cost spread economics [9][20] - The company is raising its full-year 2025 consolidated adjusted EBITDA guidance to $2.32 billion, driven by strong performance in the aggregates product line [8] - The company is positioned to benefit from ongoing infrastructure investments and anticipates low single-digit aggregates volume growth and mid-single-digit pricing gains in 2026 [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of product demand, supported by sustained federal and state investment in infrastructure [11] - The company expects continued resilience in its aggregates business, particularly from heavy non-residential demand and a recovery in residential construction [9][10] - Management noted that while affordability constraints are impacting residential construction, there are signs of normalization in mortgage rates, which could support future growth [14] Other Important Information - The company entered into a definitive agreement with Quikrete Holdings Inc. for an asset exchange, expected to close in Q4 2025, which will enhance its growth potential [9] - The company has a total liquidity of $1.1 billion as of September 30, providing flexibility for M&A opportunities [18] Q&A Session Summary Question: Balance of aggregate pricing and volumes - Management reported that pricing was up 8%, with organic pricing up 7.9%, and volumes were also up 8%, with organic volumes increasing by 5.5% [22][23] Question: Cost side expectations - Management indicated that cost performance was satisfactory and expected improvements in price-cost spread in Q4, with a projected cost per ton growth of around 2% [31][32] Question: Volume cadence and government shutdown impact - Management noted steady performance throughout the quarter and indicated that the business is resilient to government shutdowns, with state funding remaining strong [42][47] Question: Bookings and backlogs - Management highlighted strong bidding activity in heavy non-residential construction and infrastructure, with positive momentum expected into 2026 [51][52] Question: Pricing tool rollout - The Precise IQ pricing tool is expected to be fully rolled out by mid-2026, with anticipated benefits captured in the mid-single-digit pricing guidance [91][92] Question: Mid-year aggregates pricing outlook - Management expressed confidence in continued growth in public sector spending and heavy non-residential construction, which could positively impact mid-year pricing [99][100]

Financial Data and Key Metrics Changes - For Q3 2025, the company recorded revenues of $16.7 billion, a decrease of 7% operationally compared to the same period last year, primarily driven by a decline in COVID products [23] - Reported diluted earnings per share (EPS) was $0.62, while adjusted diluted EPS was $0.87, exceeding expectations due to strong gross margin and cost management performance [24] - Adjusted gross margin for the quarter was approximately 76%, reflecting product mix and strong cost management [25] Business Line Data and Key Metrics Changes - Non-COVID product performance was solid, growing 4% operationally compared to the same period last year, with significant contributions from Eliquis, the Vyndaqel family, and Nurtec [23][24] - The Vyndaqel family achieved 7% year-over-year global operational growth, while Padcev saw 13% year-over-year global operational growth [14][15] - The company’s recently launched and acquired products generated $7.3 billion in revenue, growing approximately 9% operationally year-over-year [24] Market Data and Key Metrics Changes - In international markets, the Vyndaqel family achieved 40% growth in total patients on treatment, while Nurtec led the oral CGRP class in primary care penetration in the U.S. [15] - The Prevnar family of vaccines saw 17% year-over-year international operational growth, with strong performance in pediatric pneumococcal vaccination [16] - The company expects the lung cancer market to reach approximately $70 billion by 2023, with significant growth potential in its lung cancer portfolio [12] Company Strategy and Development Direction - The company is focused on strategic investments in innovation and growth, highlighted by the proposed acquisition of MedSera and the licensing agreement with 3SBio [6][8] - The company aims to enhance its R&D pipeline and commercial capabilities, particularly in the high-growth therapeutic area of obesity [8] - The recent agreement with the U.S. government aims to lower prescription drug costs while allowing the company to invest in U.S. manufacturing [7][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver value for patients and shareholders, despite challenges in the COVID product line [5] - The company raised its adjusted diluted EPS guidance for the full year 2025, reflecting strong performance and improved cost structure [33] - Management noted that the agreement with the U.S. government will not impact 2025 guidance but may affect the 2026 financial outlook [32] Other Important Information - The company expects to achieve $1.5 billion in savings from its manufacturing optimization program by the end of 2027 [26] - The gross leverage at the end of Q3 was approximately 2.7 times, with expectations to return to target levels post-MedSera acquisition [31] - The company plans to provide guidance for 2026 by the end of the year [35] Q&A Session Summary Question: Insights on Vyndamax performance amid competition - Management acknowledged new competition but emphasized Vyndamax's unique benefits and strong market access, noting that volume growth was offset by gross-to-net headwinds [41][42] Question: Legal process regarding MedSera acquisition - Management stated that it is difficult to comment on the timing of legal proceedings but reiterated their belief that Novo's acquisition attempt is anti-competitive [48][50] Question: Plans if MedSera acquisition does not proceed - Management confirmed ongoing efforts to identify potential acquisition candidates across therapeutic areas, regardless of the MedSera outcome [52][54] Question: Dynamics of Paxlovid pricing - Management clarified that there were no significant changes in Paxlovid pricing, attributing variations to channel mix rather than material price changes [74] Question: Guidance on COVID-19 sales for the year - Management indicated that achieving the previously stated $9 billion in COVID sales is uncertain, depending on potential future COVID waves [87][90] Question: Pricing strategy for GLP-1 medicines - Management acknowledged that competition is driving prices down and that their calculations for the MedSera acquisition took this into account [94] Question: Delay in initiation of pivotal trial for pneumococcal vaccine - Management explained that the delay is due to ongoing discussions with the FDA regarding study designs and endpoints, with plans to align pediatric and adult studies [100]

Financial Data and Key Metrics Changes - For Q3 2025, the company recorded revenues of $16.7 billion, a decrease of 7% operationally compared to the same period last year, primarily driven by a decline in COVID products [23] - Reported diluted earnings per share (EPS) was $0.62, while adjusted diluted EPS was $0.87, exceeding expectations due to strong gross margin and cost management performance [24] - Adjusted gross margin for Q3 was approximately 76%, reflecting product mix and strong cost management [25] Business Line Data and Key Metrics Changes - Non-COVID product performance grew 4% operationally compared to the same period last year, with solid contributions from ELIQUIS, the VYNDAQEL family, and NURTEC [23][24] - The VYNDAQEL family achieved 7% year-over-year global operational growth, while NURTEC led the oral CGRP class in primary care penetration in the U.S. [14][15] - PADCEV achieved 13% year-over-year global operational growth, establishing itself as a standard of care for patients with locally advanced metastatic urothelial cancer [15] Market Data and Key Metrics Changes - In international markets, the company achieved 40% growth in total patients on treatment for the VYNDAQEL family [15] - The vaccines portfolio, particularly the PREVNAR family, saw 17% year-over-year international operational growth [16] - The company expects the lung cancer market to reach approximately $70 billion by 2023, with strong growth in its lung cancer portfolio [12] Company Strategy and Development Direction - The company is focused on strategic investments in innovation and growth, highlighted by the proposed acquisition of Metsera and the licensing agreement with 3SBio [6][8] - The company aims to enhance its R&D pipeline and commercial capabilities, particularly in the high-growth therapeutic area of obesity [8] - The recent agreement with the U.S. Government aims to lower prescription drug costs while allowing the company to focus on business and innovation [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to deliver value for patients and shareholders, despite challenges in the COVID product line [5] - The company raised its adjusted diluted EPS guidance for the full year 2025, reflecting strong performance and efficient cost structure [33] - Management noted that the agreement with the U.S. Government will have a diluted impact on the 2026 financial outlook but does not affect the 2025 guidance [32] Other Important Information - The company expects to achieve $1.5 billion in savings from the manufacturing optimization program by the end of 2027 [26] - Total adjusted operating expenses for Q3 were $7 billion, an increase of 21% operationally compared to last year, largely due to acquired in-process R&D expenses from the 3SBio transaction [28] - The company plans to continue investing in key products and markets to offset losses from upcoming LOEs [25] Q&A Session Summary Question: Insights on VYNDAMAX performance amid competition - Management acknowledged new competition but emphasized VYNDAMAX's unique benefits and strong market access, noting that volume growth was offset by gross-to-net headwinds [40][41] Question: Legal process regarding Metsera acquisition - Management refrained from discussing specific legal timelines but reiterated their belief that Novo's acquisition attempt is anti-competitive [47][49] Question: Plans if Metsera acquisition does not proceed - Management indicated ongoing efforts to identify potential acquisition candidates across therapeutic areas, emphasizing a proactive approach to business development [51][53] Question: Impact of manufacturing investments under the MFN agreement - Management highlighted the importance of investing in U.S. production while also improving operational cost efficiencies [59][61] Question: Clarification on PAXLOVID pricing dynamics - Management noted no significant change in pricing but acknowledged variations in channel mix affecting sales [76] Question: Guidance on COVID-19 sales for the year - Management expressed cautious optimism regarding COVID-19 sales, noting potential spikes in utilization due to future waves of the virus [88]

Financial Data and Key Metrics Changes - Martin Marietta achieved record performance in Q3 2025, with aggregates revenues of $1.5 billion, a 17% increase year-over-year [6] - Adjusted EBITDA from continuing operations rose 22% to $667 million, while total earnings per diluted share increased 16% to $6.85 [8][9] - The company raised its full-year 2025 consolidated Adjusted EBITDA guidance to $2.32 billion at the midpoint, driven by strong performance in core aggregates [9] Business Line Data and Key Metrics Changes - Aggregates gross profit increased 21% to $531 million, with gross margin expanding 142 basis points to 36% [6][16] - The specialties business reported record quarterly revenues of $131 million, a 60% increase, and gross profit of $34 million, a 20% increase [6][17] - Revenues from the continuing operations building materials business increased 10% to $1.7 billion, with gross profit rising 16% to $585 million [16] Market Data and Key Metrics Changes - The value of state and local government highway, bridge, and tunnel contract awards increased 10% year-over-year, reaching $128 billion for the 12-month period ended September 30, 2025 [10] - Heavy non-residential construction demand remains steady, particularly in data centers and warehousing, with Texas leading in hyperscaler activity [12][13] - The National Association of Home Builders' Housing Market Index rose to its highest level since April, indicating improved builder confidence [14] Company Strategy and Development Direction - The company is focused on disciplined growth and operational excellence, with the launch of SOAR 2030 aimed at enhancing its aggregates-led platform and specialties business [20] - Martin Marietta's strategic plan includes maintaining world-class safety standards and delivering attractive price-cost spread economics [9][20] - The company is committed to returning capital to shareholders, with a 5% increase in quarterly cash dividends approved [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of product demand, supported by sustained infrastructure investment and solid heavy non-residential demand [10][12] - The preliminary outlook for 2026 reflects low single-digit aggregates volume growth and mid-single-digit pricing gains, driven by ongoing infrastructure investments [9][10] - Management noted that while residential construction activity is currently constrained, there are signs of recovery expected in the latter half of 2026 [15][20] Other Important Information - The company entered into a definitive agreement with Quikrete Holdings Inc. for an asset exchange, expected to close in Q4 2025, which will enhance its operational focus [9] - The company reported the best year-to-date safety performance in its history, highlighting its commitment to safety and operational excellence [6] Q&A Session Summary Question: Balance of aggregate pricing and volumes - Management reported that pricing was up 8%, with organic pricing up 7.9%, and volumes were up 8%, with organic volumes up 5.5% [22][23] Question: Cost side expectations - Management indicated an expected improvement in price-cost spread, with Q4 cost performance implied at around 2% growth [31][32] Question: Volume cadence and government shutdown impact - Management noted steady performance throughout the quarter, with resilience against government shutdown impacts due to stable funding for infrastructure projects [42][47] Question: Bookings and backlogs - Management highlighted strong bidding activity in heavy non-residential construction and infrastructure, with positive momentum expected into 2026 [51][55] Question: Pricing tool rollout - The Precise IQ pricing tool is expected to be fully rolled out by mid-2026, with anticipated benefits captured in the mid-single-digit pricing guidance [91][92] Question: Mid-year aggregates pricing outlook - Management expressed confidence in mid-year pricing for 2026, contingent on volume growth and favorable market conditions [97][99]